Skip directly to content

Final FY18 Appropriations Resist Trump Administration’s Anti-Science Rhetoric, Affirm the Value of Research and Programs in the Elimination of HIV, Tuberculosis and Hepatitis C; Prevention Programs Must be Further Strengthened in FY19

Treatment Action Group (TAG) lauds Congress on soundly rejecting the President’s anti-science rhetoric with a fiscal year 2018 (FY18) appropriations bill that affirms the value of research and evidence-based programs to catalyze the elimination of HIV, tuberculosis (TB), and hepatitis C virus (HCV) domestically and internationally.

 “We urge Congress to build


Download this release as a PDF

New York Community Groups Call on City, State, Federal Actors to Increase Funding for Tuberculosis
Advocates alarmed that budget cuts led to first rise in TB cases in New York City in over 25 years

Erica Lessem, Treatment Action Group, 617-827-2461,
Amanda Lugg, African Services Committee, 212-222-3882, x2148,
Mika De Roo, Housing Works, 347-585-6051,

NEW YORK, March 22, 2018 – African Services Committee, FPWA, Hispanic Federation, Hispanic Health

As we discussed in Part I of this webinar series, pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant women as a vulnerable population, among others. This neglect has left pregnant women and their providers to make decisions without adequate information or guidance regarding the safety and efficacy of necessary treatments.

Part II of this webinar series was held on Wednesday, March 14th,

For Immediate Release

Annette Gaudino, 718-208-7531,

ALBANY, NY, MARCH 16 – Responding to unprecedented advocacy by community leaders, people living with hepatitis C, and communities impacted by the epidemic, Governor Cuomo today announced New York State’s commitment to eliminate hepatitis C as a public health threat. The Governor’s announcement makes New York State the first jurisdiction to declare the intention to eliminate hepatitis C, the deadliest infectious disease in the U.S.

Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

Multidrug-resistant TB (MDR-TB) is a growing problem around the world, and is difficult to treat. In 2016, the World Health Organization (WHO) recommended a shorter regimen for treating MDR-TB. Now, data from a randomized controlled trial are available. This new brief from TAG and DR-TB STAT explains what the shorter regimen is, who can receive it, and its advantages and disadvantages. 

If you want to learn even more, check out the webinar we held on the phase III trial of the shorter regimen and on the phase III trial of

Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy


For many HIV-positive people—particularly those who initiate treatment soon after infection—combination antiretroviral therapy (ART) is associated with robust improvements in CD4+ T cell counts, enhanced immune function, and a life expectancy comparable to that of similar HIV-negative individuals.

But a subset of people on ART experience limited or no recovery of CD4+ T cell counts despite achieving and maintaining undetectable HIV viral loads, and these individuals have an elevated risk of illness and death compared with counterparts who obtain greater CD4+ T cell gains.

February 16, 2018 –  On Monday, February 12th, New York State Medicaid Director Jason Helgerson made news by announcing a potential path forward in the State’s response to its major hepatitis C epidemic at the joint Senate/Assembly budget hearing on Health and Medicaid. “We already have statutory authority to look at volume based discounts [for hepatitis C treatment],” Helgerson said in response to a question about improving New Yorkers’ access to hepatitis C treatment from ranking Senate Health Committee Member Senator Gustavo Rivera. “One of the things we’re going to do is—once the prices

February 13, 2018 – Treatment Action Group (TAG) vehemently opposes cuts in the Trump administration’s fiscal year (FY) 2019 budget proposal, which severely threaten the accelerated progress of recent years towards ending the domestic and global HIV/AIDS, tuberculosis (TB) and hepatitis C virus (HCV) epidemics. The latest budget proposal, released yesterday, continues a pattern by the current administration to undermine critical programming and health care necessary to public health globally and in the United States.

“With this latest budget, the Trump administration did exactly what we knew

May 2018 – TAG is seeking to hire a Development Manager who will report to the Deputy Executive Director – Development and Operations (DED-DO) and work closely with TAG’s Executive Director, Board of Directors, the Development Committee, and program directors. The Development Manager will oversee and enhance a robust development program and will direct TAG’s annual fundraising campaign, grant cultivation and servicing, major gifts, annual benefit, smaller events, and in-print and digital appeals.